Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers

References

• Brunton SA. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. Int J Clin Pract. 2015;69(10):1071–1087. doi:10.1111/ijcp.12675
   PubMed Web of Science ®Google Scholar
• Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–559. doi:10.1038/nrd3180
   PubMed Web of Science ®Google Scholar
• Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clin Sci. 2018;132(12):1329–1339. doi:10.1042/CS20171298
   PubMed Web of Science ®Google Scholar
• Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853–872. doi:10.1002/ejhf.1170
   PubMed Web of Science ®Google Scholar
• Zafar MI. Suitability of APINCH high-risk medications use in diabetes mellitus. Eur J Pharmacol. 2020;867:172845. doi:10.1016/j.ejphar
   PubMed Web of Science ®Google Scholar
• Leiter LA, Langslet G, Vijapurkar U, Davies MJ, Canovatchel W. Simultaneous reduction in both hbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Ther. 2016;7(2):269–278. doi:10.1007/s13300-016-0163-1
   PubMed Web of Science ®Google Scholar
• Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016;38(6):1299–1313. doi:10.1111/ijcp.12675
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925–1966. doi:10.1007/s00125-022-05787-2
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee. 10 Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S144–S174. doi:10.2337/dc22-S010
   PubMedGoogle Scholar
• American Diabetes Association Professional Practice Committee. 9 Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125–S143. doi:10.2337/dc22-S009
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee. 6 Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S83–S96. doi:10.2337/dc22-S006
   PubMedGoogle Scholar
• Marx N, Davies MJ, Grant PJ, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021;9(1):46–52. doi:10.1016/S2213-8587(20)30343-0
   PubMed Web of Science ®Google Scholar
• Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19(5):403–418. doi:10.1111/jch.12597
   PubMed Web of Science ®Google Scholar
• Grossman A, Grossman E. Blood pressure control in type 2 diabetic patients. Cardiovasc Diabetol. 2017;16(1):3. doi:10.1186/s12933-016-0485-3
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task force on clinical practice guidelines. Hypertension. 2018;71(6):1269–1324. doi:10.1161/HYP.0000000000000066
   PubMed Web of Science ®Google Scholar
• Carey RM, Moran AE, Whelton PK. Treatment of Hypertension: a Review. JAMA. 2022;328(18):1849–1861. doi:10.1001/jama.2022.19590
   PubMed Web of Science ®Google Scholar
• National Medical Products Administration of China. Technical guideline for clinical pharmacokinetics of chemical drugs [in Chinese]. Available from: https://www.nmpa.gov.cn/wwwroot/gsz05106/07.pdf. Accessed March 11, 2024.
   Google Scholar
• Lago RM, Singh PP, Nesto RW. Diabetes and hypertension. Nat Clin Pract Endocrinol Metab. 2007;3(10):667. doi:10.1038/ncpendmet0638
   PubMedGoogle Scholar
• Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515–531. doi:10.1210/er.2010-0029
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5–14. doi:10.1111/j.1463-1326.2011.01511.x
   PubMed Web of Science ®Google Scholar
• Ali SS, Sharma PK, Garg VK, Singh AK, Mondal SC. The target-specific transporter and current status of diuretics as antihypertensive. Fundam Clin Pharmacol. 2012;26(2):175–179. doi:10.1111/j.1472-8206.2011.01012.x
   PubMed Web of Science ®Google Scholar
• Zhang YF, Liu YM, Yu C, et al. Tolerability, pharmacokinetic, and pharmacodynamic profiles of henagliflozin, a novel selective inhibitor of sodium-glucose cotransporter 2, in healthy subjects following single- and multiple-dose administration. Clin Ther. 2021;43(2):396–409. doi:10.1016/j.clinthera.2020.12.012
   PubMed Web of Science ®Google Scholar
• Yong X, Wen A, Liu X, et al. Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium glucose co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus. Clin Drug Investig. 2016;36(3):195–202. doi:10.1007/s40261-015-0366-7
   PubMed Web of Science ®Google Scholar
• Chen ZD, Chen Q, Zhu YT, et al. Effects of food on the pharmacokinetic properties and mass balance of henagliflozin in healthy male volunteers. Clin Ther. 2021;43(9):e264–e273. doi:10.1016/j.clinthera.2021.07.008
   PubMed Web of Science ®Google Scholar
• Wang L, Wu C, Shen L, et al. Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males. Xenobiotica. 2016;46(8):703–708. doi:10.3109/00498254.2015.1113576
   PubMed Web of Science ®Google Scholar